Kalypsys was a drug discovery company focused on the discovery and clinical development of new medicines for cancer, inflammation and metabolic disease. The companyâs mission was to leverage its proprietary automation technologies in biology and chemistry to build a sustainable drug pipeline, taking candidates from concept to clinical efficacy with unmatched speed, efficiency, and success rates. Despite having raised significant funding and having achieved owrking relationships with sveerl large players, the firm appears to have ceased operations around 2008-9
